in ,

IntegenX Teams with SAIC to Pursue Biodetection Contracts

IntegenX and Science Applications International Corporation (SAIC) recently announced that they have signed a teaming agreement to pursue Defense Threat Reduction Agency (DTRA) Indefinite Delivery/Indefinite Quantity (ID/IQ) awards supporting U.S. needs for detection of weapons of mass destruction. 

IntegenX and SAIC will work to enable warfighters to complete their missions efficiently and effectively by supplying an integrated system that provides rapid DNA-based identification of biothreat agents. 

In 2012, IntegenX successfully participated in an invitation-only U.S. Department of Defense (DOD) exercise where its RapidHIT 200 Human DNA Identification System repeatedly delivered accurate human DNA profiles from swabs, bottles, cans, sputum, hair, saliva and blood. The RapidHIT 200 is a mobile, self-contained DNA identification system that automates and accelerates the process of producing standardized DNA profiles from samples in less than 90 minutes.

The teaming agreement pairs SAIC’s biodefense capabilities with IntegenX’s rapid DNA technologies. IntegenX will leverage its RapidHIT System as part of the agreement and SAIC will integrate its software and biodefense capability with the RapidHIT to customize the system for detection of biothreats.

“The RapidHIT System will allow for rapid DNA analysis at the point of action, setting a new standard in the usage of DNA profiles to detect and identify bioagents down to the sub-species level in less than 90 minutes,” said Stevan Jovanovich, Ph.D., President and Chief Executive Officer of IntegenX. “Teaming with SAIC will give the U.S. government further access to IntegenX’s rapid DNA technology. SAIC has shown that they can integrate complex software and detection modalities for support of military biodefense applications.”

IntegenX is headquartered in Pleasanton, California. 

Source: IntegenX Press Release

Air Force Office of Scientific Research Spring Review

Ragon Institute Brings New Perspectives to Vaccine Development